INS and type 2 diabetes mellitus: To date, this has been the only study that investigated the impact of a 52-week treatment with once-weekly subcutaneous tirzepatide versus once-daily subcutaneous insulin degludec on liver fat content (LFC) in adults with inadequately controlled T2D and a fatty liver index of at least 60.